NanoViricides Inc (NNVC) Short Interest Down 44.7% in December

NanoViricides Inc (NYSEAMERICAN:NNVC) was the recipient of a significant drop in short interest in December. As of December 29th, there was short interest totalling 459,345 shares, a drop of 44.7% from the December 15th total of 830,252 shares. Based on an average daily volume of 186,490 shares, the short-interest ratio is currently 2.5 days. Approximately 0.9% of the company’s stock are short sold.

Separately, BidaskClub downgraded shares of NanoViricides from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 4th.

Shares of NanoViricides (NYSEAMERICAN:NNVC) opened at $0.84 on Thursday. The firm has a market cap of $54.72, a P/E ratio of -5.60 and a beta of 0.21. NanoViricides has a one year low of $0.83 and a one year high of $1.64.

NanoViricides (NYSEAMERICAN:NNVC) last announced its earnings results on Tuesday, November 14th. The company reported ($0.03) earnings per share for the quarter.

TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/11/nanoviricides-inc-nnvc-short-interest-down-44-7-in-december.html.

About NanoViricides

NanoViricides, Inc is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases.

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply